Search research articles
Contact Us
Filters
Showing results (1-10 of 9) with videos related to
Page
of 1
Sort By:
Clinical and Experimental Dermatology
|
August 12, 2009
Hypertrichosis in three patients treated with interferon-alpha2
F Kiecker, M A Hofmann, U Trefzer
Journal of the European Academy of Dermatology and Venereology : JEADV
|
September 22, 2006
Vitiligo-like depigmentation as a presenting sign of metastatic melanoma
F Kiecker, M Hofmann, W Sterry, et al.
Annals of Oncology : Official Journal of the European Society for Medical Oncology
|
March 7, 2019
Neuronal autoantibodies associated with cognitive impairment in melanoma patients
F Bartels, T Strönisch, K Farmer, et al.
Annals of Oncology : Official Journal of the European Society for Medical Oncology
|
September 27, 2017
Checkpoint blockade for metastatic melanoma and Merkel cell carcinoma in HIV-positive patients
M V Heppt, M Schlaak, T K Eigentler, et al.
ESMO Open
|
May 14, 2024
First-line avelumab treatment in patients with metastatic Merkel cell carcinoma: 4-year follow-up from part B of the JAVELIN Merkel 200 study
S P D'Angelo, C Lebbé, L Mortier, et al.
Cancer Immunology, Immunotherapy : CII
|
April 19, 2021
Response durability after cessation of immune checkpoint inhibitors in patients with metastatic Merkel cell carcinoma: a retrospective multicenter DeCOG study
H M Stege, M Haist, S Schultheis, et al.
Annals of Oncology : Official Journal of the European Society for Medical Oncology
|
June 12, 2016
Adjuvant treatment with pegylated interferon α-2a versus low-dose interferon α-2a in patients with high-risk melanoma: a randomized phase III DeCOG trial
T K Eigentler, R Gutzmer, A Hauschild, et al.
ESMO Open
|
May 9, 2025
Early switch from run-in with targeted to immunotherapy in advanced BRAF<sup>V600</sup>-positive melanoma: final results of the randomised phase II ImmunoCobiVem trial
E Livingstone, H J Gogas, L Kandolf, et al.
European Journal of Cancer (Oxford, England : 1990)
|
July 23, 2023
Early switch from run-in treatment with vemurafenib plus cobimetinib to atezolizumab after 3 months leads to rapid loss of tumour control in patients with advanced BRAFV600-positive melanoma: The ImmunoCobiVem phase 2 randomised trial
E Livingstone, H Gogas, L Kandolf-Sekulovic, et al.
Page
of 1
Search research articles
Search
Showing results (1-10 of 9) with videos related to
Sort By:
Page
of 1
Clinical and Experimental Dermatology
|
August 12, 2009
Hypertrichosis in three patients treated with interferon-alpha2
F Kiecker, M A Hofmann, U Trefzer
Journal of the European Academy of Dermatology and Venereology : JEADV
|
September 22, 2006
Vitiligo-like depigmentation as a presenting sign of metastatic melanoma
F Kiecker, M Hofmann, W Sterry, et al.
Annals of Oncology : Official Journal of the European Society for Medical Oncology
|
March 7, 2019
Neuronal autoantibodies associated with cognitive impairment in melanoma patients
F Bartels, T Strönisch, K Farmer, et al.
Annals of Oncology : Official Journal of the European Society for Medical Oncology
|
September 27, 2017
Checkpoint blockade for metastatic melanoma and Merkel cell carcinoma in HIV-positive patients
M V Heppt, M Schlaak, T K Eigentler, et al.
ESMO Open
|
May 14, 2024
First-line avelumab treatment in patients with metastatic Merkel cell carcinoma: 4-year follow-up from part B of the JAVELIN Merkel 200 study
S P D'Angelo, C Lebbé, L Mortier, et al.
Cancer Immunology, Immunotherapy : CII
|
April 19, 2021
Response durability after cessation of immune checkpoint inhibitors in patients with metastatic Merkel cell carcinoma: a retrospective multicenter DeCOG study
H M Stege, M Haist, S Schultheis, et al.
Annals of Oncology : Official Journal of the European Society for Medical Oncology
|
June 12, 2016
Adjuvant treatment with pegylated interferon α-2a versus low-dose interferon α-2a in patients with high-risk melanoma: a randomized phase III DeCOG trial
T K Eigentler, R Gutzmer, A Hauschild, et al.
ESMO Open
|
May 9, 2025
Early switch from run-in with targeted to immunotherapy in advanced BRAF<sup>V600</sup>-positive melanoma: final results of the randomised phase II ImmunoCobiVem trial
E Livingstone, H J Gogas, L Kandolf, et al.
European Journal of Cancer (Oxford, England : 1990)
|
July 23, 2023
Early switch from run-in treatment with vemurafenib plus cobimetinib to atezolizumab after 3 months leads to rapid loss of tumour control in patients with advanced BRAFV600-positive melanoma: The ImmunoCobiVem phase 2 randomised trial
E Livingstone, H Gogas, L Kandolf-Sekulovic, et al.
Page
of 1